News

Gilead announces ASCENT-03 study meets primary endpoint
Gilead (GILD) announced topline results from the Phase 3 ASCENT-03 study of Trodelvy. The study met its primary endpoint, demonstrating a highly statistically significant and clinically meaningful ...
Gilead (GILD) to Acquire HOOK for $10 million
Gilead Sciences Inc. (NASDAQ:GILD) has announced it will be taking over HOOKIPA Pharma Inc. (NASDAQ:HOOK) for a consideration ...
Gilead succeeds in late-stage trial for breast cancer therapy Trodelvy as a first line option
Gilead Sciences (GILD) stock in focus as cancer drug Trodelvy outperforms chemotherapy in a Phase 3 trial for advanced triple ...
Gilead to buy certain Hookipa Pharma assets for up to $10M
HOOKIPA Pharma (HOOK) stock gains as Gilead Sciences agrees to acquire some of its antiviral assets for up to $10M. Read more ...
Fierce Biotech2d
Gilead pays partner Hookipa $10M to take over HBV, HIV therapeutic vaccine programs
Gilead Sciences is paying $10 million for sole ownership of arenavirus immunotherapies for hepatitis B (HBV) and HIV ...